Skip to content
Open access · CC-BY via OpenAlex

Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19

Sanaz Rezaeian, Fatemeh Razmjooei, Masoome Pourmokhtari, Amir Abdoli, Mirza Ali Mofazzal Jahromi, Kambiz Bagheri

Heliyon · 2023 · ▲ 10 citations

Abstract

Background: Different biomarkers have been suggested as novel biomarkers of coronavirus disease 2019 (COVID-19) theragnosis. With the aim of having a better clinical management of COVID-19, we decided to determine the relationship between hematological, inflammatory, and novel biomarkers with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immunoglobulin (Ig)M and IgG antibodies. Methods: Blood samples from 127 confirmed COVID-19 patients aged 11-84 years old were collected and tested for SARS-CoV-2 IgM and IgG antibodies alongside with hematological, inflammatory, and novel biomarkers. The Spearman correlation test was utilized to analyze the correlation between these biomarkers with SARS-CoV-2 IgM and IgG antibodies. Results: -reactive protein (CRP) (r = 0.459, p = 0.000), interleukin (IL)-6 (r = 0.345, p = 0.000), IL-8 (r = 0.263, p = 0.003), neutrophil to lymphocyte ratio (NLR) (r = 0.182, p = 0.040), derived NLR (dNLR) (r = 0.197, p = 0.026), neutrophil to monocyte ratio (NMR) (r = 0.184, p = 0.038), and CRP to lymphocyte ratio (CLR) (r = 0.495, p = 0.000). Also, we find significant correlation between SARS-CoV-2 IgG antibody with hemoglobin (Hb) (r = -0.257, p = 0.004), hematocrit (Hct) (r = -0.227, p = 0.010), mean corpuscular Hb concentration (MCHC) (r = -0.212, p = 0.017), lymphocyte count (r = -0.211, p = 0.017), platelet count (r = 0.179, p = 0.044), ESR (r = 0.461, p = 0.000), CRP (r = 0.344, p = 0.000), IL-6 (r = 0.178, p = 0.046), IL-8 (r = 0.237, p = 0.007), platelet to lymphocyte ratio (PLR) (r = 0.295, p = 0.001), and CLR (r = 0.376, p = 0.000). Conclusion: Hematological biomarkers (Hb, Hct, MCHC, lymphocyte count, and platelet count), inflammatory biomarkers (ESR, CRP, IL-6, and IL-8), and novel biomarkers (dNLR, NLR, NMR, PLR, and CLR) are valuable indicators for clinical management of COVID-19.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1016/j.heliyon.2023.e22896
Canonical
link ↗
Fetched
2026-11-16 MST

Cite this

APA
Rezaeian, S., Razmjooei, F., Pourmokhtari, M., Abdoli, A., Jahromi, M.A.M., &amp; Bagheri, K. (2023). Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19. <em>Heliyon</em>. https://doi.org/10.1016/j.heliyon.2023.e22896
Vancouver
Rezaeian S, Razmjooei F, Pourmokhtari M, Abdoli A, Jahromi MAM, Bagheri K. Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19. Heliyon. 2023. doi:10.1016/j.heliyon.2023.e22896.
BibTeX
@article{sanaz2023Hemato, title = {Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19}, author = {Sanaz Rezaeian and Fatemeh Razmjooei and Masoome Pourmokhtari and Amir Abdoli and Mirza Ali Mofazzal Jahromi and Kambiz Bagheri}, journal = {Heliyon}, year = {2023}, doi = {10.1016/j.heliyon.2023.e22896}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings